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Zinc is an essential trace element integral to many cellular and immune functions. 
Zinc deficiency is highly prevalent in patients with cirrhosis and related to disease 
severity.
AIM 
To evaluate whether zinc supplementation improves clinical outcomes (disease 
severity and mortality) in patients with cirrhosis.
METHODS 
This prospectively registered systematic review (PROSPERO reference: 
CRD42018118219) included all studies in Medline, Embase or Cochrane database 
with inclusion criteria of adult human studies, comparing zinc supplementation 
of at least 28 d with standard care or placebo in patients with cirrhosis. Mortality 
and clinical severity score data were extracted. Random effects meta-analyses 
compared mortality at 6 mo and 2 years. Risk of bias was assessed using the 
National Institutes of Health quality assessment tool.
RESULTS 
Seven hundred and twelve articles were identified of which four were eligible. 
Zinc formulations and doses varied (elemental zinc 3.4-214 mg daily) for different 
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intervention periods in patients with differing etiology and severity of cirrhosis. 
Two studies were considered to be at high risk of bias. There was no significant 
difference in 6-mo mortality between patients treated with zinc versus controls 
[risk ratio 0.98 (0.90-1.05)]. Changes in severity scores were not reported in any 
study.
CONCLUSION 
Zinc supplementation is not associated with reduced mortality in patients with 
cirrhosis. Findings are limited by the small number of eligible studies and 
significant heterogeneity in intervention and patient population.
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Core tip: Zinc deficiency is highly prevalent in patients with cirrhosis and may contribute 
to disease progression and mortality. This systematic review aimed to determine whether 
zinc supplementation was associated with clinical outcomes in patients with cirrhosis. 
Meta-analysis of data from four eligible studies found that zinc supplementation was not 
associated with reduced mortality at 6 mo. No study reported changes in disease severity 
or complications. Eligible studies were highly heterogeneous with different zinc 
formulations, dosage and duration applied to varying patient populations. Further well-
designed prospective studies are required to determine whether zinc supplementation 
improves long-term clinical outcome in patients with cirrhosis.
Citation: Tan HK, Streeter A, Cramp ME, Dhanda AD. Effect of zinc treatment on clinical 
outcomes in patients with liver cirrhosis: A systematic review and meta-analysis. World J 




Chronic liver disease is a serious problem both in the United Kingdom and globally. 
Approximately 0.1% of the European population is affected by cirrhosis which account 
for 1.8% of all deaths corresponding to 170000 deaths per year[1].
Liver cirrhosis constitutes the third most common cause of premature death in the 
United Kingdom[2]. The incidence of liver cirrhosis has been increasing in the United 
Kingdom at a faster rate than the top four most-commonly diagnosed cancers (lung, 
breast, bowel and prostate)[2]. It is estimated that over 600000 people in the United 
Kingdom have serious liver disease, and 60000 of those have cirrhosis. Over 14000 
people die of liver disease each year in the United Kingdom. This figure has increased 
by 400% since the 1970s[3].
Regardless of the underlying etiology of liver disease, malnutrition becomes a 
significant clinical problem as it progresses[4]. Protein-calorie malnutrition is well 
documented and accounts for more than 60% of patients with advanced alcohol-
related cirrhosis[5]. Micronutrient deficiency including trace element deficiency has also 
been documented, which may play a role in disease pathogenesis through regulating 
antioxidant, anti-inflammatory and anti-fibrotic pathways[6].
Zinc is the second most abundant trace element in the body after iron. It forms part 
of more than 300 enzymes in the body[7]. It plays an indispensable role in cell growth, 
cell differentiation and human metabolism[7]. Therefore, zinc deficiency can contribute 
to oxidative stress, growth disorder, cognitive disorder and immune dysfunction[7]. 
Attesting to zinc’s biological importance is its known association with the activity of 
proteins, including the enzymes needed for the production and destruction of 
collagen, thus directly affecting the process of fibrosis[7]. It also possesses anti-
inflammatory and antioxidant characteristics that may indirectly affect hepatic stellate 
cells[8].
The global prevalence of zinc deficiency ranges from 4% in countries rich in animal 
protein and up to 73% in countries with plant-based diets[8]. However, up to 83% of 
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cirrhotic patients have zinc deficiency which is associated with disease severity[8]. Zinc 
deficiency in liver disease is multifactorial[9]. Changes in carbohydrate-lipid 
metabolism precipitates protein calorie and micronutrient malnutrition in patients 
with chronic liver disease[9]. Zinc is bound to albumin, alpha 2-macroglobulin and 
acids so the rate of zinc absorption is due largely to albumin concentrations[10]. As liver 
disease progresses, the level of albumin decreases and this may lead to decreased 
absorption of zinc, resulting in progression of liver disease and an increased risk of 
hepatocellular carcinoma[10]. Other factors that are responsible for zinc deficiency in 
liver cirrhosis include disturbed zinc absorption by the digestive tract as a result of the 
effects of cytokines, mainly interleukin-6 and endotoxins on gut blood flow[11]. This 
changes the small bowel intestinal mucosa and decreases zinc absorption[11]. Diuretic 
therapy also plays a factor as it increases renal zinc excretion and reduces serum 
albumin and the binding capacity for zinc.
Zinc supplementation has beneficial effects on antioxidant and inflammatory 
pathways and therefore may delay or prevent progression of cirrhosis[12,13]. We 
performed a systematic review of the published literature to determine whether zinc 
supplementation was associated with improved clinical outcomes and long-term 
survival in patients with cirrhosis. A systematic review of the role of zinc 
supplementation in the management of chronic liver diseases has been recently 
published[14]. The review evaluated its effect on response to hepatitis C virus treatment, 
hepatic encephalopathy and changes in biochemistry but did not assess the effect of 
zinc supplementation on overall long-term survival[14].
MATERIALS AND METHODS
The protocol for this systematic review was prospectively registered on the 
PROSPERO database (reference: CRD42018118219) including the literature search 
strategy.
Types of studies
We included all interventional clinical trials in humans including randomized 
controlled trials and open-label trials or observational cohort studies that compared 
zinc supplementation of at least 28 d with those of standard intervention, or placebo in 
patients with cirrhosis. Trials were included irrespective of publication status, year of 
publication or language. We excluded non-human studies and laboratory studies 
using non-clinical samples.
Patients
All adults (> 18 years old) with liver cirrhosis of any etiology, diagnosed using by liver 
histology, imaging or non-invasive methods. We excluded studies with patients under 
18 years of age and with known solid organ cancer including hepatocellular 
carcinoma.
Intervention
Studies that compared more than 28 d of zinc supplementation via any route (oral or 
parenteral) with placebo or other standard intervention for the management of 
patients with cirrhosis.
Outcome measures
The primary outcome was 1-year mortality. Secondary outcomes were 6-mo mortality, 
2-year mortality, change in severity scores [Child Pugh/ model for end-stage liver 
disease (MELD) score], complication rate from cirrhosis (hepatic encephalopathy, new 
ascites, variceal bleed, new jaundice or hepatocellular carcinoma). Studies had to 
report at least one of these outcomes to be considered for inclusions in the systematic 
review.
Search strategy
Electronic searches via MEDLINE (PubMed) 1961-present, EMBASE (1974-present), the 
Cochrane library (Cochrane Database of Systematic reviews), Cochrane Central 
Register of Controlled Trials, conference abstracts from 1980 for the following annual 
meetings: American Gastroenterology Association, American Association for the 
Study of Liver Disease, European Association for the Study of the Liver, United 
European Gastroenterology, British Society for Gastroenterology and British 
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Association for the Study of the Liver.
Comprehensive searches of the following biomedical electronic databases were also 
conducted: MEDLINE, EMBASE, PubMed and TRIPS. The search strategy included 
subject headings and keywords related to “alcohol”, “zinc” and “liver”. The full search 
strategy is presented in Supplementary material. The references in all identified 
review articles and studies were also inspected to identify other trials. Two authors 
independently assessed the eligible studies.
Selection of studies
Titles and abstracts of studies retrieved using the search strategy were screened 
independently by two authors (Tan HK and Dhanda AD) to identify eligible studies. 
For potentially relevant articles or in cases of disagreement between the two reviewers, 
the full text article was obtained and inspected independently by a third reviewer. 
Where an eligible study failed to report data on the primary or secondary outcomes, 
this information was requested from the corresponding author by email. A follow-up 
email was sent after 2 wk if no response was obtained.
Data extraction and management
Data were extracted independently by two authors (HT and AD) using a standardized, 
pre-piloted form for assessment of study quality and evidence synthesis. We studied 
the following data: Study setting and target population, study methodology, details of 
intervention, primary and secondary outcomes and method of measurement and 
information of bias. Extracted data were discussed and this discussion was 
documented.
Assessment of risk of bias in included studies
Two authors independently assessed risk of bias in the trials without masking the trial 
names using a standard checklist. Risk of bias was assessed using the National 
Institutes of Health risk of bias tools for controlled trials or observational studies[15]. 
Any discrepancies or unusual patterns were checked with an independent reviewer.
Controlled intervention studies were assessed for randomization, allocation 
method, blinding, and similarity of baseline characteristics, drop-out rate, protocol 
adherence, outcome measures and method of analysis.
Observational studies were assessed for whether there was a defined population, 
the participation of eligible population, appropriate outcome measures and analysis 
methods, loss to follow-up rates and confounding factors.
Data synthesis
We provide a narrative synthesis of the findings from the included studies, structured 
around the target population, timing of intervention, and type of outcome.
The survival (until death) rates from each study contributed to a meta-analysis of 
the efficacy of zinc supplementation in reducing mortality. If heterogeneity was 
deemed to be at least moderate as determined by the I2 statistic exceeding 30% 
detected at least at the 5% level, then the data would be meta-analyzed with a random 
effects model, otherwise a fixed effects model would be considered, if there were too 
few studies to detect heterogeneity. If any subset of studies were found to share 
characteristics that contributed to heterogeneity across all the studies, then further 
meta-analyses would be conducted on those subsets. Analysis was performed using 
the meta package[16] with a current installation in R.
RESULTS
Study selection
Seven hundred and twelve records were identified; 49 of them were retrieved and 
assessed for eligibility. Six studies met selection criteria but outcome data could not be 
obtained from one and another was an uncontrolled cohort study. Therefore, a total of 
four randomized controlled trials were included in this systematic review (Figure 1)
[17-20]. Study characteristics are presented in Table 1.
Characteristics of included studies
All four included studies were randomized controlled trials (RCTs). All but one study 
documented both gender and age. None of the studies reported ethnicity of their 
patient cohort. All four studies selected different clinical populations including 
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Table 1 Characteristics of studies included in systematic review, n (%)
Bresci et al[19] Vilar Gomez et al[18] Hayashi et al[20] Takuma et al[17]
Country Italy Cuba Japan Japan
Number of 
participants











49 56.6 (8.4) 65.1 (11.3) 66.5 (7.4)
Age (intervention 
group)
51 58.5 (8.9) 66.0 (9.9) 66.5 (5.7)
Inclusion criteria Cirrhosis (any aetiology) 
with encephalopathy
Decompensated HCV cirrhosis Cirrhosis of any 
aetiology








N/A 12.5 (3.7) N/A 11.8 (3.2)
Control group 
treatment
Placebo Placebo BCAAs BCAAs
Intervention 
group treatment
Zinc acetate Viusid Zinc sulfate + BCAAs Polaprezinc + BCAAs
Zinc preparation 
and dosage





214 3.4 45-136 51
Duration of 
intervention
6 mo 96 wk 5-6 mo 6 mo
Primary Outcome Hepatic encephalopathy 
assessments




Results No significant improvement 
in hepatic encephalopathy 
assessments
Significant improvement in overall 
survival, time to disease progression 
and cumulative incidence of HCV
Significant 
improvement in blood 
ammonia levels
Significant improvement in the 
physical component scale, but not 
the mental component scale
Duration of 
follow up
1 yr 96 wk 5-6 mo 6 mo
Continuous variables expressed as mean ± SD where available. BCAA: Branched chain amino acid; HCV: Hepatitis C virus; MELD: Model for end-stage 
liver disease; Zn: Zinc; N/A: Not applicable.
patients with cirrhosis with hepatic encephalopathy, decompensated hepatitis C 
cirrhosis, and cirrhosis with etiology not documented. All studies were conducted in 
community settings. The definition of cirrhosis was based on histological and 
biochemical confirmation in three studies; the remaining study did not specify the 
method of diagnosis of cirrhosis. Only one study was designed to test the effect of zinc 
supplementation on mortality.
Only two studies (Takuma et al[17] and Vilar Gomez et al[18]) reported severity of 
cirrhosis with mean Child Pugh scores of 6.0 and 6.3 and MELD scores of 11.8 and 
12.9.
Bresci et al[19] examined the effect of long-term oral zinc supplementation on 
recurrent hepatic encephalopathy. Ninety cirrhotic patients with recurrent 
encephalopathy were treated with 600 mg of oral zinc acetate daily for 30 d in addition 
to standard therapy. The final values of psychometric tests were better in the zinc 
group compared to the standard therapy group, but the differences were not 
statistically significant. Three deaths were reported within 6 mo (one in the placebo 
and two in the intervention group).
Tan HK et al. Zinc treatment in cirrhosis
WJH https://www.wjgnet.com 394 July 27, 2020 Volume 12 Issue 7
Figure 1  Flow diagram of study identification and selection.
Vilar Gomez et al[18] evaluated the efficacy of Viusid for 96 wk in reducing mortality 
in 100 patients with hepatitis C-related decompensated cirrhosis. Viusid was chosen 
because it is a nutritional supplement with recognized anti-inflammatory and 
antioxidant properties. It contains 11 active compounds including zinc sulphate and 
glycyrrhizic acid. Glycyrrhizin is the most active ingredient of Viusid and has anti-
inflammatory, immune-modulating and antiviral properties. The total amount of daily 
elemental zinc participants received was 3.4 mg, the lowest zinc content of any of the 
included studies. The study demonstrated a significant improvement in overall 
survival, time to disease progression and cumulative incidence of hepatocellular 
carcinoma. No differences were observed between groups for incidence of liver 
decompensation (including hepatic encephalopathy, spontaneous bacterial peritonitis, 
hepatorenal syndrome and gastrointestinal bleeding).
Hayashi et al[20] randomized 40 patients with cirrhosis to receive a combination of 
branched chain amino acids and zinc sulfate 600 mg daily for 6 mo. No deaths were 
reported during the study. They demonstrated a significant improvement in blood 
ammonia levels in the combination group, but there was no further investigation done 
to determine the mechanism of action and long-term clinical efficacy.
Takuma et al[17] investigated the effectiveness of oral polaprezinc (51 mg zinc and 174 
mg of L-carnosine daily) in 79 patients with hepatic encephalopathy. They concluded 
that oral polaprezinc did significantly improve the physical component scale, but not 
the mental component scale in patients treated with zinc supplementation. One death 
occurred in the placebo treated arm only. This study was limited by short-term follow-
up (6 mo) and non-blinded treatment allocation.
Survival
No studies reported 1-year mortality, which was the primary outcome of this 
systematic review. Three studies (Bresci et al[19], Hayashi et al[20], and Takuma et al[17]) 
reported 6-mo survival and one (Vilar Gomez et al[18]) reported 2-year survival. There is 
a substantial amount of heterogeneity across the selected study trials in terms of zinc 
formulation, dosage and patient characteristics. The heterogeneity includes dose 
quantity and frequency, formulation and types of patients.
Risk of bias assessment
We used the National Institutes of Health risk of bias tools to assess the quality of 
included studies[16]. Two studies (Vilar Gomez et al[18] and Hayashi et al[20]) were of low 
risk of bias and two studies of uncertain risk of bias (Bresci et al[19] and Takuma et al[17]). 
Risk of bias assessments are presented in Supplementary Table 1. The two studies 
scored low as a result of lack of blinding and non-similarity in baseline characteristics. 
Three out of four studies reported information on patient characteristics. Thus, 
multivariate meta-regression was not appropriate. Selection bias is likely as two 
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studies included only male subjects. Lack of information precluded a proper 
evaluation of all the risk of bias in the studies.
Meta-analysis
The I2 statistic measuring heterogeneity across all included RCTs was estimated to be 
66% and significant at the 5% level (P = 0.03). The overall effect of zinc supplements 
from the included RCTs was estimated to reduce the risk of mortality by 0.98 [95% 
confidence interval (CI): 0.90-1.05; Figure 2]. Three out of the four included studies had 
a 6-mo follow-up. The study by Vilar Gomez et al[18] reported the largest effect (risk 
ratio = 0.82), although uncertainty around the point estimate was relatively wide 
(95%CI: 0.68-0.99). Notably it had a longer 2-year follow-up, and so the meta-analysis 
was repeated without this particular study, which according to its weight, contributed 
the least to the overall estimated effect. The effect of all the studies measuring 
mortality within a 6-mo follow-up were similarly located close to, and not significantly 
different from, the null effect. Repeating the meta-analysis on these resulted in a risk 
ratio of unity (95%CI: 0.90-1.05) for the effect of zinc supplementation on the risk of 
mortality over a 6-mo follow-up (Figure 3).
DISCUSSION
This systematic review identified just four studies that assessed whether zinc 
supplementation is associated with improved clinical outcomes in patients with 
cirrhosis. All four eligible studies were highly heterogeneous in terms of patient 
characteristics, treatment formulation and duration. Four different zinc preparations, 
with daily elemental zinc doses ranging from 3.4 to 214 mg daily, were tested. Two of 
these (Viusid, polaprezinc) contained other active compounds, which could have 
contributed to the positive clinical outcome, for example Viusid contains only 3.4 mg 
of elemental zinc along with 10 other active ingredients. Three studies tested zinc 
supplementation in combination with other intervention (branch chain amino acids 
and nutritional support).
A further limitation is the low mortality rate in all eligible studies. With such a low 
event rate, any effect of zinc on mortality is difficult to determine. This suggests that 
either severity of cirrhosis was mild or follow-up duration was insufficient. Only two 
studies reported severity of cirrhosis with the majority of subjects classified as Child 
Pugh class A. Two out of four studies were designed to determine the benefit of zinc 
on hepatic encephalopathy and not powered to detect differences in mortality.
Both Vilar Gomez et al[18] and Takuma et al[17] suggested the most likely beneficiaries 
from zinc supplementation would be those with portal hypertension and leaky gut 
with its resultant risk of sepsis. Preclinical and in vivo evidence suggests that zinc may 
reduce gut permeability[21]. Zinc carnosine (polaprezinc) improved in vitro gut 
epithelial cell migration and proliferation[21]. In healthy volunteers, zinc carnosine 
treatment reversed both indomethacin-induced and extreme exercise-induced gut 
leakiness[22]. To test the benefit of a combination strategy of zinc supplementation and 
treatment of gut leakiness in advanced cirrhosis, long-term studies in patients with 
portal hypertension are required.
Given the limited data, we are unable to determine whether zinc supplementation 
improves survival or reduces disease severity in patients with cirrhosis. Research is 
still needed to confirm the preclinical benefits seen with zinc supplementation on anti-
fibrotic, anti-inflammatory and antioxidant processes. To determine whether zinc 
supplementation improves clinical outcomes of patients with cirrhosis, further high 
quality studies are required to ascertain the optimal zinc formulation, dose, duration 
of treatment and patient population to treat.
In conclusion, this systematic review has highlighted the paucity of high quality 
studies investigating the effect of zinc supplementation in patients with cirrhosis. 
Eligible studies were of variable design and quality. The primary analyses all had 
substantial heterogeneity reflecting the differences in study design, inclusion criteria 
and primary outcome. The difference in etiology and severity of liver cirrhosis also 
make the effect of zinc supplementation difficult to interpret. With a plausible 
rationale for benefit from zinc supplementation, there is a strong argument to develop 
well designed studies in patients stratified clearly by severity of cirrhosis and presence 
of portal hypertension to determine the long term outcome of zinc supplementation.
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Figure 2  Forest plot of all included randomized controlled trials using a random effects model. Risk ratio 0.98 (95% confidence interval: 0.90-
1.05); Heterogeneity: I2 = 66%; P = 0.03. CI: Confidence interval.
Figure 3  Forest plot of included randomized controlled trials reporting 6 mo mortality using a random effects model (Vilar Gomez et al[18] 
excluded). Risk ratio 1.00 (95% confidence interval: 0.96-1.05), Heterogeneity: I2 = 0%; P = 0.52. CI: Confidence interval.
ARTICLE HIGHLIGHTS
Research background
Zinc is an essential trace element integral to many cellular and immune functions. Zinc 
deficiency is highly prevalent in patients with cirrhosis and related to disease severity.
Research motivation
Zinc supplementation has been used to treat complications of cirrhosis including 
hepatic encephalopathy. However, it is unknown whether zinc supplementation in 
patients with cirrhosis results in a change in the risk of progression of cirrhosis or 
death.
Research objectives
This study aimed to evaluate whether zinc supplementation improves clinical 
outcomes and long-term survival in patients with cirrhosis.
Research methods
A systematic review was performed including all studies in Medline, Embase or 
Cochrane database with inclusion criteria of adult human studies, comparing zinc 
supplementation of at least 28 d with standard care or placebo in patients with 
cirrhosis. Mortality and clinical severity score data were extracted. Random effects 
meta-analyses determined risk of mortality in patients receiving zinc supplementation 
versus comparator at 6 mo and 2 years. Risk of bias was assessed using the National 
Institutes of Health quality assessment tool.
Research results
Seven hundred and twelve articles were identified of which four were eligible. Zinc 
formulations and doses varied for different intervention periods in patients with 
differing etiology and severity of cirrhosis. Two studies were considered to be at high 
risk of bias. There was no significant difference in 6-mo mortality between patients 
treated with zinc versus controls. Changes in severity scores were not reported in any 
study.
Research conclusions
Findings are limited by the small number of eligible studies and significant 
heterogeneity in intervention and patient population. Zinc supplementation is not 
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statistically associated with reduced mortality or improved long term outcome in 
patients with cirrhosis.
Research perspectives
There is substantial heterogeneity in study design, inclusion criteria and primary 
outcome. The difference in etiology and severity of liver cirrhosis also make the effect 
of zinc supplementation difficult to interpret. Further well-designed prospective 
studies are required to determine whether zinc supplementation improves long-term 
clinical outcome in patients with cirrhosis.
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